Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Almost three-quarters of prescribed pain meds are opioids, and Vertex could change that. VRTX stock broke out to a record high Thursday.

The Surprising $5 Billion Opportunity That Drove Vertex Pharmaceuticals Stock To A Record High

Intuitive Surgical

Teladoc

Vertex Pharmaceuticals is raking in profits from its flagship business, but the best may be yet to come. Intuitive Surgical is recovering from the slowdown in procedure volumes during the height of the pandemic.

3 Top Healthcare Stocks to Buy for October

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2023 financial results on Monday, November 6, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2023 Earnings Call.” The conference call will be webcast live and a link to the webcast can.

Vertex to Announce Third Quarter 2023 Financial Results on November 6

VRTX has a robust investment thesis here, due to the near monopoly in the Cystic Fibrosis therapy market. Its pipeline has also shown promising early data while obtaining Fast Track and Orphan Drug Designations, implying potentially expedited review processes and commercialization. Despite the upcoming patent expirations over the next five years, VRTX's top-line prospects remain excellent, dominated by the growing global sales for TRIKAFTA/KAFTRIO.

Vertex Pharmaceuticals Deserves Its Monopoly Premium Indeed

CNBC's Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.

Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'

Ginkgo Bioworks Holdings

Eli Lilly

While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotech stocks as much.

3 Biotech Stocks Ready to Break Out in 2024

Applied Industrial Technologies

Applied Materials

In the world of investing, there's one indicator that really stands out: Free Cash Flow (FCF) yield. Think of it as a sign that a company is good at making money and using it wisely.

3 Top Ranked Stocks with Superior Free Cash Flow Yield

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the b.

Vertex Appoints Michel Lagarde to its Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). Prior to VX-880 treatment, all six patients enrolled had long-standing T1D with no endogenous insulin secretion, required.

Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting

CRISPR Therapeutics

Poseida Therapeutics

In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three companies are emerging as pioneers, guiding the world into a new era of therapeutic possibilities.

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

Beam Therapeutics

bluebird bio

Pfizer

In September, Cathie Wood and Ark Invest bought shares of Beam Therapeutics more than a dozen times. Beam Therapeutics is a clinical-stage drugmaker with a unique approach to developing new gene therapies.

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?

Axsome Therapeutics

Vertex Pharmaceuticals is awaiting a regulatory decision on what may become its next blockbuster. Axsome Therapeutics aims to launch several products over the next few years.

2 Top Biotech Stocks to Buy in October

Visa

Vertex Pharmaceuticals' strategy of developing therapies for unmet needs is paying off big time. Visa's dominance in its niche of the financial services industry could help it deliver outsized returns.

Got $1,000? 2 No-Brainer Stocks to Buy

Bank of America

PayPal

Bank of America is a bargain thanks to the fallout from the banking crisis this year. PayPal Holdings is much stronger than its stock performance indicates.

3 Magnificent Stocks That Are Screaming Buys in October

Upstart Holdings

The rare-disease drug industry and the lending industry both serve huge addressable markets. Vertex has built a profitable business on the back of its cystic fibrosis drug franchise, and it's still early days.

2 Brilliant Growth Stocks to Invest $2,000 in Right Now

Disney

Devon Energy

Mastercard

Target

These five stocks could hardly be more different, but they have one important thing in common: All look like great buys in October 2023. From retail to biotech, these stocks showcase their resilience and strategic adaptability amid unpredictable market fluctuations.

5 Top Stocks for October

AbbVie

ACELYRIN Inc

Clinical trials are a difficult and grueling process for companies. The FDA and other regulatory agencies require the highest possible standards in order to approve new drugs.

Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs

In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast research and development (R&D), the rewards can be significant.

Don't Miss the Boom: 3 Biotech Stocks Set to Explode Higher

Chewy

Regardless of what happens with the economy, people continue to spend money on pets and healthcare. Chewy is building a powerhouse business on the back of recurring revenue streams and diversification.

Buying These 2 Remarkable Growth Stocks in Any Market Could Be a Genius Move

Arch Capital

Bunge Global SA

General Electric

Meta leads five resilient stocks worth watching. But investors need to be patient amid the market correction.

Meta Stock Leads 5 Names Showing Resilience In Market Downturn

Brookfield Infrastructure Partners L.P.

Microsoft

Brookfield Infrastructure should deliver strong organic growth and continue to expand via acquisitions. Microsoft is a leader in nearly all of the top technologies of the future.

3 Unstoppable Stocks to Buy and Hold for the Next 20 Years

Vertex Pharmaceuticals shows exceptional total return performance (900% since 2006), propelled by strong cash flow and innovative therapies. VRTX focuses on treating cystic fibrosis and is awaiting trial results for a potential breakthrough in CF treatment. With a robust pipeline and strategic investments, Vertex's future growth appears promising, with significant secular growth tailwinds.

A Total Return Superstar: Vertex Pharmaceuticals

Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.

Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use

Advanced Micro Devices

Medtronic

Moderna

Intellia Therapeutics

NVIDIA

Before investing in a trend, it's important to make sure it isn't a fad of the moment and instead has staying power. Artificial intelligence and CRISPR gene editing are two popular trends that could be game-changers down the road.

2 Top Trends to Invest $500 In Right Now

There are a lot of contenders in Wood's Ark Invest portfolio that could be 10-baggers. Most of those stocks have some downsides, though.

News for Vertex Pharmaceuticals Stock (VRTX)